Monday, 3 Nov 2025
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Subscribe
Life Care News
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
    NewsShow More
    Over 600 Customers Visit Liberty General Insurance Branches During Customer Experience Week 2025, Celebrating Trust and Service Excellence
    Over 600 Customers Visit Liberty General Insurance Branches During Customer Experience Week 2025, Celebrating Trust and Service Excellence
    02/11/2025
    Enfinity Global to Supply 400 GWh Guarantees of Origin to VW Kraftwerk GmbH to Support Sustainable Mobility
    Enfinity Global to Supply 400 GWh Guarantees of Origin to VW Kraftwerk GmbH to Support Sustainable Mobility
    02/11/2025
    Isolation to Inclusion: Znabou’s Story
    Isolation to Inclusion: Znabou’s Story
    02/11/2025
    Over 600 Customers Visit Liberty General Insurance Branches During Customer Experience Week 2025, Celebrating Trust and Service Excellence
    China Pioneers Urban Health-Climate Solutions as Risks Hit Record High, Offers New Pathways for Global South
    02/11/2025
    Over 600 Customers Visit Liberty General Insurance Branches During Customer Experience Week 2025, Celebrating Trust and Service Excellence
    CGTN: How China champions openness and multilateralism to build Asia-Pacific community
    01/11/2025
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
  • 🔥
  • news
  • global
  • Business
  • announced
  •  and
  • today
  •  the
  • june
  • company
  • Tech
Font ResizerAa
Life Care NewsLife Care News
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Search
  • Home
  • Business
    • Business Wire
    • Globenews Wire
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Follow US
© 2022 Foxiz News Network. Ruby Design Company. All Rights Reserved.
Business

Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer

PRNW Agency
Last updated: 21/07/2025 10:19 PM
PRNW Agency
Share
3 Min Read
Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer
SHARE
Minaris Advanced Therapies Welcomes Orla Cloak as Chief Executive Officer

PHILADELPHIA, July 21, 2025 /PRNewswire/ — Minaris Advanced Therapies is pleased to announce the appointment of Dr. Orla Cloak as Chief Executive Officer. 

- Advertisement -

Dr. Cloak is a seasoned executive with over 20 years of commercial leadership experience in the Pharma and Life Science industries. She brings with her a proven track record of driving innovation, operational excellence, sustainable business growth and strategic leadership. Prior to joining Minaris Advanced Therapies, Orla held several leadership positions at Lonza over a 17-year period, most recently serving as Senior Vice President and Head of the Lonza Bioscience business. She holds a Bachelor of Science Degree from University College Dublin and a Doctorate in Microbiology from the University of Ulster.

- Advertisement -

Iain Baird, Chairman of the Board, Minaris Advanced Therapies commented: “On behalf of the board, I am delighted to welcome Orla to Minaris Advanced Therapies. Her leadership will be instrumental to achieving our mission of supporting customers to successfully commercialize their innovative therapies.”

- Advertisement -

Orla Cloak, Chief Executive Officer, Minaris Advanced Therapies commented: “I am honored to join Minaris Advanced Therapies at such a pivotal time. I look forward to working with the talented team here to build on the company’s strong foundations and drive its next phase of growth.”

- Advertisement -

About Minaris Advanced Therapies:

- Advertisement -

Minaris Advanced Therapies is a global contract development and manufacturing organization (CDMO) and contract testing provider focused exclusively on Cell and Gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing.

- Advertisement -

Minaris Advanced Therapies is a portfolio company of Altaris.

- Advertisement -

www.minaris.com

- Advertisement -

About Altaris:

- Advertisement -

Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit www.altariscap.com

- Advertisement -

Media Contact:

- Advertisement -

Tihesha Aaron

- Advertisement -

corp.communications@minaris.com

- Advertisement -

Logo – https://mma.prnewswire.com/media/2679651/Minaris_Advanced_Therapies_Logo.jpg

- Advertisement -

Photo – https://mma.prnewswire.com/media/2734229/Dr_Orla_Cloak.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/minaris-advanced-therapies-welcomes-orla-cloak-as-chief-executive-officer-302508861.html

- Advertisement -
Pheton Holdings Ltd Issues Statements Addressing Recent Market Activity and Misleading Rumors
SIG SAUER Celebrates Major Milestone: 100 Million Round Annual 6.8mm Ammunition Capacity
World’s Largest Toy, Baby, Licensing & Preschool Expo: Connecting Integrated Sourcing Under One Roof
Flipster and Kaia Partner to Extend Stablecoin Access Across Asia
Cambrex Unveils $120 Million Investment to Expand API Manufacturing and Strengthen U.S. Drug Supply Resilience
TAGGED:advancedannounceappointmentboardbringsBusinesschiefcloakcommercialexecutiveexperienceindustriesjulyleadershiplifelonzaminarisnewsofficerorlapharmaphiladelphiapleasedprovenrecordscienceseasonedtherapiestrackuniversitywelcomesyears
Share This Article
Facebook Copy Link Print
- Advertisement -

Your Trusted Source for Accurate and Timely Updates!

Our commitment to accuracy, impartiality, and delivering breaking news as it happens has earned us the trust of a vast audience. Stay ahead with real-time updates on the latest events, trends.
FacebookLike
XFollow
PinterestPin
InstagramFollow
YoutubeSubscribe
LinkedInFollow
MediumFollow

Most Selling Products

Top Picks, Trending Now – Discover the Best Sellers!
Tecno Camon 20 Premier 5G

Tecno Camon 20 Premier 5G

Dark Welkin | 8GB RAM + 512GB Storage (Expandable RAM up to 16GB) | Industry’s 1st 50MP RGBW-Pro Camera | Segment-First 108MP Ultra-Wide Macro Lens | 6.67" 120Hz 10-bit AMOLED In-Display

iQOO Z10 Lite 5G

iQOO Z10 Lite 5G

Titanium Blue | 6GB RAM + 128GB Storage | Dimensity 6300 5G with 433K+ AnTuTu Score | Robust 6000mAh Battery | IP64 Rated + Military-Grade Shock Resistance

OnePlus 13s

OnePlus 13s

Black Velvet | 12GB RAM + 256GB Storage | Flagship Snapdragon® 8 Elite Chipset | Exceptional Battery Life in a Compact Form | Lifetime Display Warranty Included

Samsung Galaxy A55 5G

Samsung Galaxy A55 5G

Awesome Iceblue | 8GB RAM + 256GB Storage | Premium Metal Frame | 50MP OIS Main Camera with Nightography | IP67 Water & Dust Resistance | Gorilla Glass Victus+ | sAMOLED Display with Vision Booster

You Might Also Like

Silynxcom Announces First Half of 2025 Financial Results, Expands Client Diversity and Raised .9M to Support Growth
Tech

Silynxcom Announces First Half of 2025 Financial Results, Expands Client Diversity and Raised $2.9M to Support Growth

28/09/2025
Spotlight on Chery International User Summit: LEPAS to Fully Unlock Value and Invite Global Users on a Journey of Elegant Co-Creation
Automobile

Spotlight on Chery International User Summit: LEPAS to Fully Unlock Value and Invite Global Users on a Journey of Elegant Co-Creation

24/09/2025
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Health

New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

21/09/2025
2025 FISU World Cup: Football Begins in Dalian
Entertainment

2025 FISU World Cup: Football Begins in Dalian

25/09/2025
Life Care News
Facebook Twitter Youtube Rss Medium

Life Care News:


We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.

Top Categories
  • Home
  • Business
  • News
  • Tech
  • Health
  • Sports
  • Entertainment
  • Automobile
Usefull Links
  • About Us
  • Contact Us
  • Terms and Conditions
  • Privacy Policy
Copyright © 2015 – 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Life Care NewsLife Care News
Copyright © 2015 - 2025 LifeCareNews Network. All Rights Reserved. LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?